抗IL5/Rα生物制剂治疗重度哮喘的5年个体水平应答稳定性:长期有效但持续缓解罕见
该研究纳入2016年1月至2020年6月丹麦所有启动抗IL5/Rα治疗的重度哮喘成人患者482例,每年评估五域缓解标准并随访5年。结果显示5年总体缓解率为17.6-23.1%,仅7.7%患者达到持续5年缓解,缓解呈动态变化且约15.2%的患者每年缓解后次年不再满足标准。
要点
- 抗IL5/Rα治疗5年总体缓解率17.6-23.1%,仅7.7%达持续5年缓解
- 37.4%患者至少实现1年缓解,部分在2或3年才首次缓解
- 未缓解主要由永久性FEV1损害和持续未控制症状驱动
核心结论
- 重度哮喘患者对IL5/Rα生物制剂应答良好,5年内各域均有显著改善
- 缓解是动态状态,可间歇复发,当前标准下持续长期缓解罕见
研究设计与样本
- 丹麦全国性真实世界队列研究,纳入2016年1月至2020年6月启动抗IL5/Rα治疗的成人重度哮喘患者482例
- 每年评估五域缓解标准并随访5年
主要发现
- 5年总体缓解率为17.6-23.1%
- 约15.2%的患者每年缓解后次年不再满足缓解标准
- 37.4%患者至少实现1年缓解,部分在2或3年首次缓解
- 仅7.7%患者达到持续5年缓解
- 33.6%患者实现5年持续无急性发作且无维持口服糖皮质激素
关键数值与推荐
- 五域缓解标准:无急性发作、无维持口服糖皮质激素、FEV1>80%预计值、哮喘控制问卷评分<1.5、未换用非抗IL5/Rα生物制剂
- 基线时13.9%符合无急性发作,66.0%符合无维持口服糖皮质激素,29.7%符合FEV1>80%预计值,26.5%符合ACQ<1.5
- 第5年时18.7%患者换用非抗IL5/Rα生物制剂
临床怎么用
- 临床应认识到抗IL5/Rα治疗下缓解呈动态变化,需定期评估而非单次判断
- 对FEV1永久损害和症状持续未控制者,需考虑调整治疗策略
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For a decade, anti-interleukin-5/receptor α (IL5/Rα) has been available to treat severe asthma, with marked reductions in exacerbation rates and maintenance oral corticosteroid burden. However, little is known about long-term, real-world sustained remission. We aimed to assess the stability of response to anti-IL5/Rα over 5 years. METHODS: All Danish adults initiating anti-IL5/Rα for severe asthma during January 2016 through June 2020 were included. Five-domain remission (no exacerbations, no maintenance oral corticosteroid, forced expiratory volume in 1 s (FEV1) >80% predicted, Asthma Control Questionnaire score <1.5 and no switch to non-anti-IL5/Rα) was assessed annually for 5 years. RESULTS: In total, 482 patients were included (median age 56 years, 48% female). At baseline, 13.9% fulfilled the criteria of no exacerbations, 66.0% of no maintenance oral corticosteroid, 29.7% of FEV1 >80% predicted and 26.5% of Asthma Control Questionnaire score <1.5. At year 5, 18.7% had switched to a non-anti-IL5/Rα biologic.The overall remission rate was 17.6-23.1% over 5 years. However, remission was found to be dynamic; approximately 15.2% of patients in remission per annum did not fulfil the remission criteria the subsequent year. At least 1 year of remission was achieved by 37.4% of patients, with some patients first achieving remission during year 2 or 3.Only 7.7% achieved sustained 5-year remission. Failure to achieve remission was driven by permanently impaired FEV1 and persistent uncontrolled symptoms. 5-year sustained freedom from exacerbations and maintenance oral corticosteroid use was seen in 33.6% of patients. CONCLUSIONS: Patients with severe asthma respond well to anti-IL5/Rα, with substantial improvements across all domains over 5 years. Remission is a dynamic state with intermittent relapses, and sustained long-term remission is rare using current domains.
引用
- Håkansson, Hansen, Soendergaard, et al. Long-term efficacy but rare sustained remission: individual-level 5-year stability in anti-IL5/Rα biologic therapy response for severe asthma. Eur Respir J. 2026. PMID: 41309267. doi:10.1183/13993003.00926-2025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。